StockData
Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$7.70−0.23 (-2.90%)

Close on Nov 13, 2026Market cap $77.29MP/E –Yield –

Atara Biotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Atara Biotherapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$12.99M. For fiscal 2025 it was -$50.94M. The highest annual figure on record is -$5.97M in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$50.94M–
FY2024Dec 31, 2024-$68.72M–
FY2023Dec 31, 2023-$192.98M–
FY2022Dec 31, 2022-$270.43M–
FY2021Dec 31, 2021-$220.52M–
FY2020Dec 31, 2020-$180.76M–
FY2019Dec 31, 2019-$235.63M–
FY2018Dec 31, 2018-$179.77M–
FY2017Dec 31, 2017-$87.50M–
FY2016Dec 31, 2016-$60.03M–
FY2015Dec 31, 2015-$37.16M–
FY2014Dec 31, 2014-$16.63M–
FY2013Dec 31, 2013-$5.97M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$879.00K–
Q2 FY2026Jun 30, 2026-$3.34M–
Q1 FY2026Mar 31, 2026-$3.07M–
Q4 FY2025Dec 31, 2025-$5.70M–
Q3 FY2025Sep 30, 2025-$9.79M–
Q2 FY2025Jun 30, 2025-$7.32M–
Q1 FY2025Mar 31, 2025-$28.14M–
Q4 FY2024Dec 31, 2024-$24.47M–
Q3 FY2024Sep 30, 2024-$3.99M–
Q2 FY2024Jun 30, 2024-$10.65M–
Q1 FY2024Mar 31, 2024-$29.61M–
Q4 FY2023Dec 31, 2023-$50.41M–
Q3 FY2023Sep 30, 2023-$51.35M–
Q2 FY2023Jun 30, 2023-$52.80M–
Q1 FY2023Mar 31, 2023-$38.43M–
Q4 FY2022Dec 31, 2022-$56.88M–
Q3 FY2022Sep 30, 2022-$65.06M–
Q2 FY2022Jun 30, 2022-$63.96M–
Q1 FY2022Mar 31, 2022-$84.53M–
Q4 FY2021Dec 31, 2021-$34.27M–
Q3 FY2021Sep 30, 2021-$58.98M–
Q2 FY2021Jun 30, 2021-$61.58M–
Q1 FY2021Mar 31, 2021-$65.70M–
Q4 FY2020Dec 31, 2020-$4.12M–
Q3 FY2020Sep 30, 2020-$52.96M–
Q2 FY2020Jun 30, 2020-$56.64M–
Q1 FY2020Mar 31, 2020-$67.04M–
Q4 FY2019Dec 31, 2019-$58.69M–
Q3 FY2019Sep 30, 2019-$52.15M–
Q2 FY2019Jun 30, 2019-$54.59M–
Q1 FY2019Mar 31, 2019-$70.20M–
Q4 FY2018Dec 31, 2018-$57.42M–
Q3 FY2018Sep 30, 2018-$48.10M–
Q2 FY2018Jun 30, 2018-$39.43M–
Q1 FY2018Mar 31, 2018-$34.82M–
Q4 FY2017Dec 31, 2017-$24.94M–
Q3 FY2017Sep 30, 2017-$20.23M–
Q2 FY2017Jun 30, 2017-$20.30M–
Q1 FY2017Mar 31, 2017-$22.03M–
Q4 FY2016Dec 31, 2016-$21.16M–

More Atara Biotherapeutics figures

See a number that looks wrong?